NCT01562626View on ClinicalTrials.gov

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
TumorsNeoplasmsCancer
Interventions
DRUG

APS001F

APS001F infusion on Days 1,2,3 of each 28 day cycle.

DRUG

Flucytosine (5-FC)

oral doses on Days 11-15 and 18-22, each 28 day cycle

DRUG

10% maltose

10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.

Trial Locations (2)

55455

University of Minnesota, Minneapolis

77030

MD Anderson, Houston

Sponsors
All Listed Sponsors
lead

Anaeropharma Science, Inc.

INDUSTRY

NCT01562626 - Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors | Biotech Hunter | Biotech Hunter